Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

80
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
80
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

68
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
68
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

57
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
57
Master Transcription Regulators02:23

Master Transcription Regulators

8.0K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
8.0K
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

77
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
77
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

60
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying Inheritance Patterns of Allelic Imbalance, using Integrative Modeling and Bayesian Inference.

bioRxiv : the preprint server for biology·2026
Same author

Modeling gene regulatory perturbations via deep learning from high-throughput reporter assays.

bioRxiv : the preprint server for biology·2026
Same author

Enhancer hubs govern chromatin topology and Th17 cell identity.

bioRxiv : the preprint server for biology·2026
Same author

Structured Pooling Improves Detection of Rare Regulatory Mutations in Population-Scale Reporter Assays.

bioRxiv : the preprint server for biology·2026
Same author

Reprogramming of neuronal genome function and phenotype by astrocytes.

bioRxiv : the preprint server for biology·2026
Same author

Functional dissection of complex trait variants at single-nucleotide resolution.

Nature·2026

Related Experiment Video

Updated: Mar 10, 2026

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

13.6K

Decoding the role of regulatory element polymorphisms in complex disease.

Christopher M Vockley1, Alejandro Barrera2, Timothy E Reddy2

  • 1Department of Cell Biology, Duke University Medical Center, Durham, NC 27710, United States; Department of Biostatistics & Bioinformatics, and Center for Genomic & Computational Biology, Duke University Medical Center, Durham, NC 27710, United States.

Current Opinion in Genetics & Development
|December 17, 2016
PubMed
Summary

Genetic variations in gene regulatory elements cause human diseases. Advances in genome editing help establish causality, but functional gene annotation is now a key challenge for patient benefit.

More Related Videos

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.4K
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.5K

Related Experiment Videos

Last Updated: Mar 10, 2026

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

13.6K
In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.4K
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.5K

Area of Science:

  • Genetics
  • Genomics
  • Molecular Biology

Background:

  • Genetic variations in gene regulatory elements are implicated in a spectrum of human diseases, from developmental disorders to complex conditions like obesity and diabetes.
  • Historically, chromosomal rearrangements and more recently, single nucleotide variants (SNVs) in regulatory regions have been linked to disease pathogenesis.
  • These SNVs can alter critical regulatory processes including transcription factor binding, enhancer activity, and chromatin modifications.

Purpose of the Study:

  • To review the historical context and recent advancements in understanding the regulatory mechanisms underlying human diseases.
  • To highlight the evolving landscape of disease causality determination through genetic and epigenomic studies.
  • To identify emerging challenges in translating these findings into clinical applications.

Main Methods:

  • This review synthesizes current literature on genetic variation, gene regulation, and human disease.
  • It discusses the impact of technological advancements, such as genome-editing and epigenome-editing technologies.
  • The review examines the role of functional annotation in understanding disease mechanisms.

Main Results:

  • Genetic variations in non-coding regulatory elements are significant contributors to human disease.
  • Genome-editing technologies have improved the ability to establish causal links between genetic variants and disease.
  • The focus is shifting from identifying causal variants to understanding their functional consequences.

Conclusions:

  • Establishing the causal regulatory mechanisms of disease is becoming more routine.
  • Functional annotation of target genes presents a significant bottleneck for clinical translation.
  • Future efforts must address this challenge to realize patient benefits from genetic discoveries.